Abeona Therapeutics Inc vs Comfort Systems USA Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while Comfort Systems USA Inc trades at $1,677.95 (market cap $58.94B). The key difference: Comfort Systems USA Inc is far larger — about 138.9× Abeona Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FIX | |
|---|---|---|
Market Cap | $424.33M | $58.94B |
Sector | Health | Technology |
52-Week High | $7.45 | $2.07K |
52-Week Low | $4.17 | $680.86 |
Enterprise Value | $279.23M | $57.42B |
Dividend Yield | — | 0.21% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
FIX trades at $1,694.55, down 1.11% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating estimates with EPS of $12.53 versus $10.45 expected, driven by robust data center demand. Revenue grew to $11.2B in 2026, with net profit margin expanding to 12.77%. Analyst consensus is bullish with a $2,170 price target, though valuation multiples like P/E of 41.22 appear elevated.
Outlook remains positive given record backlog and AI-driven demand, but risks include high execution demands and premium valuation. The stock offers growth exposure to the construction and data center sectors, supported by institutional interest and consistent dividend payments, though investors should monitor capacity constraints and competitive pressures.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →